| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Acridone-4-carboxylic acid targets heme, preventing free heme-mediated protein oxidation and degradation. By interacting with heme, it inhibits the formation of protein carbonyls, which are markers of oxidative protein damage. The compound's mechanism is related to its ability to chelate or interact with heme, thereby reducing its pro-oxidant activity.
|
|---|---|
| ln Vitro |
In vitro, Acridone-4-carboxylic acid inhibits protein carbonyl formation with an IC50 of 43 µM. It interacts with heme and prevents free heme-mediated protein oxidation and degradation. This activity suggests its potential as an antioxidant or cytoprotective agent against heme-induced oxidative damage. However, detailed cellular activity data are limited.
|
| ln Vivo |
In vivo, Acridone-4-carboxylic acid is expected to show protective effects against heme-mediated oxidative damage. However, specific in vivo efficacy data and detailed animal study results are not extensively reported in the available literature. The compound is primarily used as a research tool.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for Acridone-4-carboxylic acid involve assessing its interaction with heme. Spectroscopic methods such as UV-Vis or fluorescence spectroscopy can be used to study the binding of the compound to heme. The inhibition of protein carbonyl formation is measured using a colorimetric or immunoblotting assay after incubating the compound with a protein and a heme-mediated oxidation system.
|
| Cell Assay |
In vitro cellular assays for Acridone-4-carboxylic acid are performed using cell lines to assess its cytoprotective effects against heme-mediated oxidative stress. Cells are treated with heme and the compound, and protein carbonyl levels, cell viability, and markers of oxidative stress are measured. However, specific protocols are not extensively reported.
|
| Animal Protocol |
In vivo animal studies with Acridone-4-carboxylic acid would typically be conducted in models of hemolysis or heme-induced organ damage. The compound would be administered, and its effects on markers of oxidative stress and tissue damage would be assessed. However, specific protocols are not detailed in the available literature.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of Acridone-4-carboxylic acid are not extensively reported. It has a molecular weight of 239.23. It is soluble in DMSO at 100 mg/mL. Specific parameters such as oral bioavailability, half-life, and tissue distribution are not detailed.
|
| Toxicity/Toxicokinetics |
The toxicity profile of Acridone-4-carboxylic acid is not extensively reported in the available literature. As a research compound, it is for research use only and not for human therapeutic use. No specific toxicity data are detailed.
|
| Additional Infomation |
Acridone-4-carboxylic acid (ACA, Compound 2c) is an acridone analogue that interacts with heme and prevents free heme-mediated protein oxidation and degradation. It inhibits protein carbonyl formation with an IC50 of 43 µM. The compound is used as a research tool to study heme-mediated oxidative damage and is available for research purposes only.
|
| Molecular Formula |
C14H9NO3
|
|---|---|
| Molecular Weight |
239.226163625717
|
| Exact Mass |
239.058
|
| CAS # |
24782-64-7
|
| PubChem CID |
3560758
|
| Appearance |
Off-white to light yellow solid powder
|
| Density |
1.397g/cm3
|
| Boiling Point |
469.9ºC at 760 mmHg
|
| Melting Point |
>185 °C(dec.)
|
| Flash Point |
238ºC
|
| Vapour Pressure |
1.24E-09mmHg at 25°C
|
| Index of Refraction |
1.673
|
| LogP |
2.379
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
18
|
| Complexity |
368
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C2=C(C=CC=C2)NC3=C(C(O)=O)C=CC=C13
|
| InChi Key |
BATAOFZEDHPRTM-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H9NO3/c16-13-8-4-1-2-7-11(8)15-12-9(13)5-3-6-10(12)14(17)18/h1-7H,(H,15,16)(H,17,18)
|
| Chemical Name |
9-oxo-10H-acridine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~418.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.1801 mL | 20.9004 mL | 41.8008 mL | |
| 5 mM | 0.8360 mL | 4.1801 mL | 8.3602 mL | |
| 10 mM | 0.4180 mL | 2.0900 mL | 4.1801 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
